ALAlvotech ALVO · NASDAQ
$5.31 +2.71% (+$0.14)
- Market cap
- $1.89B
- Enterprise value
- $3.20B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.9x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- 20.2%
- Gross margin
- 60.4%
- Net margin
- -36.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.18
- Free float
- 30.5%
About the company
Alvotech (ALVO) is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines. The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Lisa Graver
Employees
1,279
Headquarters
Luxembourg
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number